Frailty in Aging and the Search for the Optimal Biomarker: A Review

• Published in: Biomedicines Vol. 10; no. 6; p. 1426
• Main Authors: Sepúlveda, Magdalena, Arauna, Diego, García, Francisco, Albala, Cecilia, Palomo, Iván, Fuentes, Eduardo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16-06-2022; MDPI
• Subjects: Aging; Antioxidants; Artificial intelligence; Biological markers; Biomarkers; Cardiac muscle; Clinical medicine; Cytokines; diagnosis; Frail elderly; Frailty; Genotype & phenotype; Geriatrics; Growth factors; Health aspects; Hematology; Identification and classification; Inflammation; Older people; Oxidative stress; Phenotypes; Physiological aspects; Physiology; Population; Proteins; Quality of life; Review; Risk factors; Sarcopenia; Skeletal muscle; Vitamins; Chile; frailty; diagnosis; older people; aging; biomarkers
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10061426

In the context of accelerated aging of the population worldwide, frailty has emerged as one of the main risk factors that can lead to loss of self-sufficiency in older people. This syndrome is defined as a reduced state of physiological reserve and functional capacity. The main diagnostic tools for frailty are based on scales that show deficits compared to their clinical application, such as the Fried frailty phenotype, among others. In this context, it is important to have one or more biomarkers with clinical applicability that can objectively and precisely determine the degree or risk of frailty in older people. The objective of this review was to analyze the biomarkers associated with frailty, classified according to the pathophysiological components of this syndrome (inflammation, coagulation, antioxidants, and liver function, among others). The evidence demonstrates that biomarkers associated with inflammation, oxidative stress, skeletal/cardiac muscle function, and platelet function represent the most promising markers of frailty due to their pathophysiological association with this syndrome. To a lesser extent but with the possibility of greater innovation, biomarkers associated with growth factors, vitamins, amino acids, and miRNAs represent alternatives as markers of this geriatric syndrome. Likewise, the incorporation of artificial intelligence represents an interesting approach to strengthening the diagnosis of frailty by biomarkers.